Iantrek
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
151 E Post Rd # 110-111, White Plains, N...Website
iantrekmed.comRevenue
$12.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Iantrek
Founded by ophthalmic innovator Sean Ianchulev, MD, MPH, Iantrek is a venture-funded medical technology company pioneering bio-interventional and micro-interventional products for ophthalmic surgery. The companys portfolio includes AlloSert Uveo, AlloFlo Uveo, CanaloFlo, and C.Rex bio-interventional and micro-interventional solutions for the management of glaucomaExplore more
Iantrek Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Iantrek your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Iantrek had a recent Job posting/layoffs
Earning: See what the market has to say on Iantrek recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Iantrek has new funding data
Product Launch: Get notified when Iantrek launches new products
Check out if Iantrek is spiking on competitors!
Check if Iantrek has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Iantrek
Iantrek, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Iantrek as Masked Content
Find 3 more new buyers
Compare Similar Companies to Iantrek
Compare insights from companies similar to Iantrek, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Iantrek is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Iantrek is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Iantrek.
Iantrek financials insights
Gather financial insights about Iantrek, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$5.2M
2022
Series B
$23M
2025
Series C
$42M
Private Equity
$34.7M
2026
Debt
$30M
Iantrek Tech Stack
A closer look at the technologies used by Iantrek
Most Recent Scoops
Funding
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
Iantrek has more open roles in Sales than it has had at any time in the past 12 months with an increased focus that include Regional Sales, Sales Territory Management, Customer Advocacy, Quota Achievement, Sales Performance Management, Sales Forecasting, and Medical Device Sales.
Hiring Plans
Hiring Plans
Iantrek has more open roles in Medical & Health than it has had at any time in the past 12 months with an increased focus that include Glaucoma, Medical Devices, and Patient Advocacy.
Hiring Plans
Funding
Funding
Iantrek News & Media
Iantrek Announces Commercial Launch of AlloFlo™ Uveo, the Only Surgical Treatment Targeting the Uveoscleral Pathway in Glaucoma
AlloFlo™ Uveo expands interventional options for glaucoma surgeons and patientsAlloFlo™ Uveo Achieves Key Milestones Ahead of Launch: 7 Peer-Reviewed Studies & 3,000 U.S. Cases
Two new milestone publications confirm robust efficacy and safety profile of bio-Interventional uveoscleral outflow enhancement technology Two new milestone publications confirm robust efficacy and safety profile of bio-Interventional uveoscleral outflow enhancement technologyIantrek Raises $42 Million Series C to Launch AlloFlo™ Uveo, a Breakthrough Interventional Glaucoma Therapy
Iantrek Raises $42 Million Series C to Launch AlloFlo™ Uveo, a Breakthrough Interventional Glaucoma Therapy, and expand commercial access to match demand.Iantrek Hits 2,000 Procedures for New Bio-Interventional Technology - AlloFlo™ Uveo
CEO Adam Szaronos provides a technology update at the Eyecelerator Conference CEO Adam Szaronos provides a technology update at the Eyecelerator Conference
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Iantrek
Sign Up For FreeTo access detailed company insights
Founded by ophthalmic innovator Sean Ianchulev, MD, MPH, Iantrek is a venture-funded medical technology company pioneering bio-interventional and micro-interventional products for ophthalmic surgery. The companys portfolio includes AlloSert Uveo, AlloFlo Uveo, CanaloFlo, and C.Rex bio-interventional and micro-interventional solutions for the manage... Read More
